Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALG 055009

Next Previous
Drug Profile

ALG 055009

Alternative Names: ALG-009; ALG-055009; ALG-THR-β; THR-Beta agonist - Aligos Therapeutics; THR-β-agonists - Aligos Therapeutics

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aligos Therapeutics
  • Class Amides; Amines; Chlorophenols; Ethers; Hepatoprotectants; Pyridazines; Small molecules; Triazines
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in France (PO)
  • 26 Mar 2025 Efficacy and adverse event data from the phase IIa HERALD trial in Non-alcoholic steatohepatitis released by Aligos Therapeutics
  • 25 Mar 2025 Aligos Therapeutics initiates enrollment in a phase I relative bioavailability trial (In volunteers) in USA (PO, Capsule) (NCT06959888)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top